LUNG CANCER UPDATES

ESMO HIGHLIGHTS

19-23 DE OCTUBRE 2018, MUNICH

ESTADIOS LOCALMENTE AVANZADOS

Dr. Joaquim Bosch

Iniciativa científica de:

GECP

Grupo Español de Cáncer de Pulmón

Spanish Lung Cancer Group

Estadios localmente avanzados

- Situación clínica compleja, que requiere de valoración en un comité de tumores multidisciplinar.

- Representa aproximadamente un tercio de los pacientes con cáncer de pulmón.

- Hay que distinguir entre pacientes operables y/o resecables.

Estadios precoces



Estadios precoces



Estadios precoces

PACIFIC – PROGRESSION-FREE SURVIVAL

PFS= 16.8 VS 5.6



MUNICH 2018 ESMO congress

Antonia S et al, NEJM 2017

Estadios precoces

LUNG CANCER UPDATES
ESMO HIGHLIGHTS
19-23 DE OCTUBRE 2018, MUNICH

PACIFIC - OVERALL SURVIVAL

OS= NR VS 28.7
OS 2ª= 66.3% VS 55.6%
HR=0.65
PD-L1 >1%



MUNICH 2018 ESMO congress

Antonia S et al, NEJM 2018

Iniciativa científica de:
GECP
Grupo Español de Cáncer de Pulmón
Spanish Lung Cancer Group

Estadios precoces



Estadios precoces



Estadios precoces



Estadios precoces

Early stage NSCLC
> neoadjuvant IO ph3 study



Estadios precoces



Estadios precoces

Neoadjuvant treatment

	N	Median	Range
Cycles	45	3.0	(1.0-3.0)

CYCLES	N	%
1	3	5
3	43	95
Total	46	100.0

All patients received three neoadjuvant cycles except for the three patients still being treated.

Clinical response

	N	%
Complete response (CR)	3	10.0
Partial response (PR)	18	60.0
Stable disease (SD)	9	30.0
Total	30	100.0

No progressive disease has been observed.

GECP
Grupo Español de Cáncer de Pulmón
Spanish Lung Cancer Group

MUNICH 2018 ESMO congress

Provencio M et al, WCLC Toronto 2018

Estadios precoces

Ongoing Targeted Clinical Trials for NSCLC in Neoadjuvant setting

ClinicalTrials.gov ID	Phase	Drug	Setting	Endpoint	No. of Pts
NCT02347839	2	Gefitinib → surgery → gefitinib	Neoadjuvant, Stage III NSCLC, EGFRm	Resectability rate	37
NCT02804776	2	Gefitinib	Induction (4 weeks) for resectable NSCLC, EGFRm	Biomarker evaluation	40
NCT03433469	**2**	**Osimertinib**	**Neoadjuvant, Stage I–IIIA, resectable NSCLC, EGFRm**	**MPR**	**27**
NCT01407822 (EMERGING)	2, 3	Erlotinib versus gemcitabine / cisplatin	Neoadjuvant, Stage IIIA NSCLC, EGFRm	ORR	70
NCT03349203	2	Icotinib	Adjuvant / neoadjuvant, Stage IIIB NSCLC, EGFRm	ORR	60
NCT02820116	2	Icotinib	Neoadjuvant, Stage III NSCLC, EGFRm	Complete resection rate	67
NCT03088930	2	Crizotinib	Neoadjuvant, Stage I–IIIA, resectable NSCLC, with an activating alteration in ALK, ROS1, or MET	ORR	18
UMIN000017906 (SAKULA)	2	Ceritinib	Neoadjuvant, Stage II–IIIA, resectable NSCLC, with an activating alteration in ALK	MPR	7/19

MUNICH 2018 ESMO congress

National Cancer Center Hospital East, Kashiwa, Chiba, Japan